MAP2K7 and melanoma: Concluding, although it has been described that dedifferentiated AXL-expressing melanoma cells are considered to be resistant to targeted therapy using RAF and MEK inhibitors,9,10,13 our data suggest that AXL+ melanoma cells may also escape to immunotherapy, whereas MITF-expressing melanoma cells seem sensitive to immune-mediated killing.